UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

The health portfolio has previously been dubbed a 'poisoned chalice' — so what are the challenges facing the new ministers in health, mental health, and disability? Jennifer Carroll MacNeill ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

The National Union of Seamen, Ports, and Allied Workers (NUSPAW) of TUC Ghana, has extended its heartfelt congratulations to Ebow Mensah on his recent re-appointment as the Administrator of Premix ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and Sanofi that you may have missed. Expected readouts in diabetes, cancer and depression ...

Objective The children's head injury algorithm for the prediction of important clinical events (CHALICE) is one of the strongest clinical prediction rules for the management of children with head ...

7 CIRI/Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD), Goethe University, Frankfurt, ...